FDA Clears Casgevy Gene Therapy for Sickle Cell Disease in Children as Young as 2

The Food and Drug Administration expanded the approved use of Casgevy on July 1, making it the first gene therapy cleared for children as young as 2 years old with sickle cell disease or transfusion-dependent beta thalassemia, according to a press announcement reviewed directly from the FDA's website.

The supplemental approval, granted to Vertex Pharmaceuticals, drops the eligible age from 12 years down to 2. That change matters in practical terms. Sickle cell disease doesn't wait for adolescence. Pain crises can begin in infancy, and the cumulative organ damage from repeated vaso-occlusive crises starts early.

Casgevy works by editing a patient's own blood stem cells outside the body. The cells are collected, modified using CRISPR/Cas9 technology to boost production of fetal hemoglobin, and then returned as a single intravenous infusion. According to the FDA announcement, the edited cells are engrafted into the bone marrow, where elevated fetal hemoglobin levels prevent red blood cells from forming the rigid, sickle shape that blocks vessels and causes crises.

The clinical data supporting the label expansion came from ongoing phase 3 trials, CLIMB-141 and CLIMB-151, which enrolled patients aged 5 to 11 years. According to Healio's reporting on the approval, all eight of the evaluable patients in the sickle cell arm achieved the primary endpoint: no protocol-defined severe vaso-occlusive crises for 12 consecutive months within the first two years after infusion. In the beta thalassemia arm, eight of nine evaluable patients achieved transfusion independence for at least 12 consecutive months, with a median transfusion-free duration of more than 20 months.

The FDA extrapolated those results down to age 2, which is standard regulatory practice when the biology of a disease is consistent across a pediatric age range and direct trial data in the youngest patients are still being gathered.

There's nothing simple about delivering this therapy. Casgevy requires full myeloablative conditioning before infusion, meaning children go through intensive chemotherapy to clear their bone marrow before the edited cells go in. That preparation carries real risks, including febrile neutropenia and delayed platelet recovery. The FDA's labeling also flags warnings for engraftment failure and potential off-target genome editing. This isn't a therapy administered in a community clinic; it requires a specialized transplant center.

According to Vertex's news release on the approval, the expanded label makes roughly 5,500 additional children in the U.S. eligible for the treatment.

Megha Kaushal, M.D., acting deputy director of the FDA's Office of Therapeutic Products and a pediatric hematologist, said in the agency's announcement that these disorders "carry a heavy burden for children and their families, affecting growth, development, and long-term health in profound ways."

Haydar Frangoul, M.D., medical director of HCA Healthcare's Sarah Cannon Transplant and Cellular Therapy Program and an investigator in the Casgevy trials, put the timing argument plainly in a statement cited by Epocrates: earlier access to this therapy lets clinicians and families consider treatment before years of cumulative damage from these life-shortening diseases take hold.

That framing lines up with what families who've spent years managing sickle cell in a child already know. Every hospitalization for a pain crisis is a risk. Every year of transfusion dependence adds iron overload and its own complications. The question for pediatric hematologists now isn't whether this approval is meaningful. It's which two-year-olds are healthy enough to survive the conditioning regimen it requires.

Sources cited:
- FDA Press Announcement, FDA Approves First Gene Therapy for Young Children with Sickle Cell Disease (https://www.fda.gov/news-events/press-announcements/fda-approves-first-gene-therapy-young-children-sickle-cell-disease)
- Vertex Pharmaceuticals News Release, Vertex Announces US FDA Approval for Expanded Use of CASGEVY (https://news.vrtx.com/news-releases/news-release-details/vertex-announces-us-fda-approval-expanded-use-casgevyr-treatment)
- Healio, FDA expands Casgevy approval to children 2 years and older with sickle cell disease (https://www.healio.com/news/hematology-oncology/20260702/fda-expands-casgevy-approval-to-children-2-years-and-older-with-sickle-cell-disease)
- Pharmacy Times, FDA Expands Casgevy Approval to Children as Young as 2 Years (https://www.pharmacytimes.com/view/fda-expands-casgevy-approval-to-children-as-young-as-2-years-with-sickle-cell-disease-or-transfusion-dependent--thalassemia)
- Epocrates, FDA expands Casgevy label to younger children with sickle cell disease (https://www.epocrates.com/online/article/fda-expands-casgevy-label-to-younger-children-with-sickle-cell-disease)